{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:26:50Z","timestamp":1765268810244},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abrocitinib, an oral once\u2010daily Janus kinase 1 selective inhibitor, is under development for the treatment of atopic dermatitis. This phase 1, nonrandomized, open\u2010label, single\u2010dose study (NCT03660241) investigated the effect of renal impairment on the pharmacokinetics, safety, and tolerability of abrocitinib and its metabolites following a 200\u2010mg oral dose. Twenty\u2010three subjects with varying degrees of renal function (normal, moderate, and severe impairment) were enrolled. Active moiety exposures were calculated as the sum of unbound exposures for abrocitinib and its active metabolites. For abrocitinib, the adjusted geometric mean ratios (GMRs; %) for area under the concentration\u2010time curve from time 0 extrapolated to infinite time and maximum plasma concentration were 182.91 (90% confidence interval [CI], 117.09\u2010285.71) and 138.49 (90% CI, 93.74\u2010204.61), respectively, for subjects with moderate renal impairment vs normal renal function; corresponding GMRs were 121.32 (90% CI, 68.32\u2010215.41) and 99.11 (90% CI, 57.30\u2010171.43) for subjects with severe impairment vs normal renal function. Metabolite exposures generally increased in subjects with renal impairment. The GMRs of unbound area under the concentration\u2010time curve from time 0 extrapolated to infinite time and maximum plasma concentration of active moiety were 210.20 (90% CI, 154.60\u2010285.80) and 133.87 (90% CI, 102.45\u2010174.92), respectively, for subjects with moderate renal impairment vs normal renal function. Corresponding values were 290.68 (90% CI, 217.39\u2010388.69) and 129.49 (90% CI, 92.86\u2010180.57) for subjects with severe renal impairment vs normal renal function. Abrocitinib was generally safe and well tolerated. Both moderate and severe renal impairment led to higher exposure to abrocitinib active moiety, suggesting that abrocitinib dose should be reduced by half for patients with moderate or severe renal impairment.<\/jats:p><jats:p>ClinicalTrials.gov identifier: NCT03660241<\/jats:p>","DOI":"10.1002\/jcph.1980","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:07:47Z","timestamp":1634083667000},"page":"505-519","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites"],"prefix":"10.1002","volume":"62","author":[{"given":"Ellen Q.","family":"Wang","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Pfizer Inc.  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu","family":"Le","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Winton","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakambari","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta","family":"Raje","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Global Product Development Pfizer Inc.  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Dowty","sequence":"additional","affiliation":[{"name":"Pharmacokinetics, Metabolism, and Dynamics, Medicine Design Pfizer Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimal K.","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Pfizer Inc.  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0128-z"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.05.055"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.09.076"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00436-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-2-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.020"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18730"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1624683"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.1003"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2020.12.6.1063"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.026"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","unstructured":"DowtyM YangX LinJ et\u00a0al.The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF\u201004965842 a JAK1 inhibitor in clinical development.Presented at: 12th International Society for the Study of Xenobiotics (ISSX) Meeting; July 28\u201031 2019;Portland OR.","DOI":"10.1016\/j.dmpk.2020.04.191"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13612"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1858"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V122326"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000017575.50319.77"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.8.1065"},{"key":"e_1_2_10_23_1","unstructured":"European Medicines Agency.Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf. Published December 17 2015. Accessed April 19 2021."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.190"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16004"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054031"},{"key":"e_1_2_10_29_1","unstructured":"FostvedtL WojciechowskiJ MalhotraBK et\u00a0al.Zero\u2010inflated beta regression exposure\u2010response modeling of the Eczema Area and Severity Index score for patients taking abrocitinib.Presented at: American Conference on Pharmacometrics \u2013 Virtual; October 4\u20107 2020."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1980","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T13:53:34Z","timestamp":1693144414000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/jcph.1980"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1980","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"2021-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}